Premium
Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis
Author(s) -
Brown M.,
Noursadeghi M.,
Boyle J.,
Davidson R.N.
Publication year - 2005
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.06670.x
Subject(s) - amphotericin b , amphotericin b deoxycholate , leishmaniasis , cutaneous leishmaniasis , regimen , medicine , leishmania , visceral leishmaniasis , meglumine antimoniate , leishmania braziliensis , antifungal , pharmacology , dermatology , immunology , gastroenterology , parasite hosting , caspofungin , world wide web , computer science
Summary Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg −1 day −1 and then as an outpatient at 3 mg kg −1 twice weekly for a further three weeks, a total of 40 mg kg −1 . Liposomal amphotericin offers a well‐tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.